$DVAX
DYNAVAX TECHNOLOGIES CORP

2024 Q2 Form 10-Q Financial Statement

#000095017024055653 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $73.80M $50.79M
YoY Change 22.48% 8.24%
Cost Of Revenue $11.99M $10.97M
YoY Change -11.46% -25.46%
Gross Profit $61.81M $39.82M
YoY Change 32.32% 23.63%
Gross Profit Margin 83.76% 78.41%
Selling, General & Admin $41.66M $44.07M
YoY Change 12.38% 20.58%
% of Gross Profit 67.4% 110.65%
Research & Development $14.95M $13.53M
YoY Change 14.59% -0.57%
% of Gross Profit 24.19% 33.97%
Depreciation & Amortization $1.135M $1.124M
YoY Change 3.18% 10.96%
% of Gross Profit 1.84% 2.82%
Operating Expenses $56.61M $57.59M
YoY Change 12.96% 14.85%
Operating Profit $5.198M -$17.77M
YoY Change -252.66% -41.26%
Interest Expense $1.698M $1.695M
YoY Change 0.59% 0.53%
% of Operating Profit 32.67%
Other Income/Expense, Net $0.00 $101.0K
YoY Change -100.0% 339.13%
Pretax Income $14.91M -$11.50M
YoY Change 254.31% -51.52%
Income Tax $3.500M -$2.800M
% Of Pretax Income 23.48%
Net Earnings $11.39M -$8.721M
YoY Change 231.86% -64.16%
Net Earnings / Revenue 15.43% -17.17%
Basic Earnings Per Share $0.09 -$0.07
Diluted Earnings Per Share $0.08 -$0.07
COMMON SHARES
Basic Shares Outstanding 130.9M 130.6M
Diluted Shares Outstanding 154.5M 130.2M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $735.6M $723.5M
YoY Change 7.94% 10.98%
Cash & Equivalents $112.5M $132.0M
Short-Term Investments $623.1M $591.5M
Other Short-Term Assets $21.31M $19.79M
YoY Change 21.8% 26.64%
Inventory $62.46M $61.81M
Prepaid Expenses
Receivables $61.65M $44.16M
Other Receivables $976.0K $1.993M
Total Short-Term Assets $882.0M $851.3M
YoY Change 10.6% 2.55%
LONG-TERM ASSETS
Property, Plant & Equipment $36.11M $36.41M
YoY Change -3.57% -4.58%
Goodwill $2.007M $2.022M
YoY Change -1.57% -0.79%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $73.67M $73.45M
YoY Change -0.33% -0.66%
Total Long-Term Assets $134.3M $135.3M
YoY Change -3.36% -3.22%
TOTAL ASSETS
Total Short-Term Assets $882.0M $851.3M
Total Long-Term Assets $134.3M $135.3M
Total Assets $1.016B $986.6M
YoY Change 8.53% 1.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.555M $2.431M
YoY Change 40.33% -66.68%
Accrued Expenses $48.49M $45.84M
YoY Change 43.15% 64.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.19M $56.00M
YoY Change 38.63% -38.81%
LONG-TERM LIABILITIES
Long-Term Debt $223.3M $223.0M
YoY Change 0.51% 0.51%
Other Long-Term Liabilities $198.0K $203.0K
YoY Change -43.27% -42.33%
Total Long-Term Liabilities $198.0K $203.0K
YoY Change -43.27% -42.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.19M $56.00M
Total Long-Term Liabilities $198.0K $203.0K
Total Liabilities $373.5M $368.1M
YoY Change 3.97% -9.38%
SHAREHOLDERS EQUITY
Retained Earnings -$927.9M -$939.3M
YoY Change -1.82% -0.97%
Common Stock $1.576B $1.562B
YoY Change 3.14% 3.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $642.8M $618.5M
YoY Change
Total Liabilities & Shareholders Equity $1.016B $986.6M
YoY Change 8.53% 1.72%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $11.39M -$8.721M
YoY Change 231.86% -64.16%
Depreciation, Depletion And Amortization $1.135M $1.124M
YoY Change 3.18% 10.96%
Cash From Operating Activities $10.71M -$16.68M
YoY Change -61.8% -160.38%
INVESTING ACTIVITIES
Capital Expenditures $779.0K $749.0K
YoY Change 3.73% -41.62%
Acquisitions
YoY Change
Other Investing Activities -$27.99M $3.580M
YoY Change -209.87% -107.01%
Cash From Investing Activities -$28.77M $2.831M
YoY Change -216.36% -105.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.415M -4.203M
YoY Change 381.29% 36.02%
NET CHANGE
Cash From Operating Activities 10.71M -16.68M
Cash From Investing Activities -28.77M 2.831M
Cash From Financing Activities -1.415M -4.203M
Net Change In Cash -19.47M -18.25M
YoY Change -137.1% -33.99%
FREE CASH FLOW
Cash From Operating Activities $10.71M -$16.68M
Capital Expenditures $779.0K $749.0K
Free Cash Flow $9.934M -$17.43M
YoY Change -63.61% -166.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001029142
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-34207
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Dynavax Technologies Corporation
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0728374
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Powell Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2024Q1 dei City Area Code
CityAreaCode
510
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
848-5100
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
DVAX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130891710
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132033000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150279000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
591505000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
592023000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2024Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
44161000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
40607000
CY2024Q1 us-gaap Other Receivables
OtherReceivables
1993000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
3926000
CY2024Q1 us-gaap Inventory Net
InventoryNet
61806000
CY2023Q4 us-gaap Inventory Net
InventoryNet
53290000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19788000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18995000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
851286000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
859120000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36413000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37297000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23392000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24287000
CY2024Q1 us-gaap Goodwill
Goodwill
2022000
CY2023Q4 us-gaap Goodwill
Goodwill
2067000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73452000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74325000
CY2024Q1 us-gaap Assets
Assets
986565000
CY2023Q4 us-gaap Assets
Assets
997096000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2431000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5245000
CY2024Q1 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3137000
CY2023Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2982000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45841000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49448000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4593000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4520000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
56002000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62195000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2516000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2802000
CY2024Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
222984000
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
222698000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28559000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29720000
CY2024Q1 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2023Q4 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
203000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000
CY2024Q1 us-gaap Liabilities
Liabilities
368085000
CY2023Q4 us-gaap Liabilities
Liabilities
375024000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130859000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129530000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
131000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
130000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1562027000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1554634000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4373000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2108000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-939305000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-930584000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
618480000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
622072000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
986565000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
997096000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50790000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46925000
CY2024Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
10966000
CY2023Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
14712000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13528000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13605000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44065000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36543000
CY2024Q1 dvax Bad Debt Expense
BadDebtExpense
0
CY2023Q1 dvax Bad Debt Expense
BadDebtExpense
12313000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
68559000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
77173000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17769000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30248000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
9468000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
6597000
CY2024Q1 us-gaap Interest Expense
InterestExpense
1695000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1686000
CY2024Q1 dvax Sublease Expense Income
SubleaseExpenseIncome
-1602000
CY2023Q1 dvax Sublease Expense Income
SubleaseExpenseIncome
1598000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
101000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11497000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23716000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2776000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
616000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8721000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130200000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127921000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130200000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127921000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8721000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2024Q1 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-1457000
CY2023Q1 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
666000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-808000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
572000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2265000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1238000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10986000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23094000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
622072000
CY2024Q1 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
1635000
CY2024Q1 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-8159000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
904000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13014000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2265000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8721000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
618480000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
CY2023Q1 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
239000
CY2023Q1 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-5237000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
777000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10034000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1238000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
563732000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8721000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24332000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1124000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1013000
CY2024Q1 dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
824000
CY2023Q1 dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
642000
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
1264000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2024Q1 dvax Sublease Loss
SubleaseLoss
4765000
CY2023Q1 dvax Sublease Loss
SubleaseLoss
0
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4528000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3498000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13014000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10034000
CY2024Q1 dvax Bad Debt Expense
BadDebtExpense
0
CY2023Q1 dvax Bad Debt Expense
BadDebtExpense
12313000
CY2024Q1 dvax Non Cash Interest Expense
NonCashInterestExpense
1695000
CY2023Q1 dvax Non Cash Interest Expense
NonCashInterestExpense
1686000
CY2024Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
1621000
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-30336000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9780000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1753000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4800000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1304000
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-118000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-677000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2640000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4096000
CY2024Q1 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
1025000
CY2023Q1 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
793000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6368000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5001000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16679000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27622000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
150685000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
185301000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
154265000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
134250000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
749000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1283000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2831000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52334000
CY2024Q1 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
1635000
CY2023Q1 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
239000
CY2024Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
904000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
777000
CY2024Q1 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
6742000
CY2023Q1 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
4106000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4203000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3090000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-201000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18252000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27651000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132304000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
174560000
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
949000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
32000
CY2024Q1 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
0
CY2023Q1 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
71307000
CY2024Q1 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
0
CY2023Q1 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
-60337000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
355000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
926000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
278000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">informed estimates and assumptions that may affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes, including amounts of revenues and expenses during the reported periods. Management’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates, judgments and methodologies. Significant estimates and assumptions in the unaudited condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets; valuation procedures for right-of-use assets and operating lease liabilities; valuation of inventory; research and development expenses; contingencies and share-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132033000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150279000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
174350000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
271000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
277000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
210000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
207000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132304000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150556000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
174560000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
371571000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
371273000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
220546000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
220232000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
592117000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
591505000
CY2024Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
19660000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
27256000
CY2024Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
33969000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18954000
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8177000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7080000
CY2024Q1 us-gaap Inventory Net
InventoryNet
61806000
CY2023Q4 us-gaap Inventory Net
InventoryNet
53290000
CY2024Q1 dvax Opearting Lease Rent Area
OpeartingLeaseRentArea
75662
CY2024Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
3500000
CY2024Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4800000
CY2024Q1 dvax Collection Of Termination Payment
CollectionOfTerminationPayment
1300000
CY2024Q1 us-gaap Sublease Income
SubleaseIncome
1900000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
1600000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1416000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1388000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1900000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4557000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4496000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28559000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29720000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
33116000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
34216000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received Remainder Of Fiscal Year
LessorSubleaseRentalsPaymentsToBeReceivedRemainderOfFiscalYear
3700000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5716000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
6127000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6966000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
6342000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6107000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
6564000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6038000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
6794000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6201000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
16191000
CY2024Q1 dvax Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
15021000
CY2024Q1 dvax Lessor Sublease Rentals Payments To Be Received
LessorSubleaseRentalsPaymentsToBeReceived
45718000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
46049000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12933000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
33116000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2024Q1 dvax Description Of Avecia Supply Agreement
DescriptionOfAveciaSupplyAgreement
On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). Included in the balance of our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B, as of March 31, 2024 and December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement totaled $7.4 million for each period, anticipated within the next 12 months.
CY2024Q1 dvax Aggregate Minimum Commitment
AggregateMinimumCommitment
7400000
CY2023Q4 dvax Aggregate Minimum Commitment
AggregateMinimumCommitment
7400000
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12300000
CY2023Q2 dvax Prepayment Of Advance Payment
PrepaymentOfAdvancePayment
13500000
CY2023Q2 dvax Repayment Of Advance From Customer
RepaymentOfAdvanceFromCustomer
47400000
CY2023Q3 us-gaap Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
38000000
CY2024Q1 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
20
CY2024Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
300600000
CY2024Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
CY2023Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
286000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
277000
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1695000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1686000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50790000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46925000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8721000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8721000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24332000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24332000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130200000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130200000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127921000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127921000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39704000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37165000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130859129
CY2022Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
15000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10120000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37388000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1505000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.46
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
240000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.82
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.52
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
89000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.46
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11294000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.05
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M20D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23032000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11050000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
11.03
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y4M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
22954000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7653000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.56
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M2D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
20912000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
13014000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10034000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2800000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.242
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.026

Files In Submission

Name View Source Status
0000950170-24-055653-index-headers.html Edgar Link pending
0000950170-24-055653-index.html Edgar Link pending
0000950170-24-055653.txt Edgar Link pending
0000950170-24-055653-xbrl.zip Edgar Link pending
dvax-20240331.htm Edgar Link pending
dvax-20240331.xsd Edgar Link pending
dvax-ex10_1.htm Edgar Link pending
dvax-ex31_1.htm Edgar Link pending
dvax-ex31_2.htm Edgar Link pending
dvax-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
dvax-20240331_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable